Drug Profile
SC 002 - Stemcentrx
Alternative Names: SC-002Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Stemcentrx
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Small cell lung cancer
- Discontinued Neuroendocrine tumours
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Second-line therapy or greater) in USA (IV, Infusion)
- 05 Dec 2018 Phase-I development in Small cell lung cancer is ongoing (AbbVie pipeline, December 2018)
- 05 Oct 2018 Discontinued - Phase-I for Neuroendocrine tumours (Second-line therapy or greater) in USA (IV)